

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project (RPP) decision paper

Review of TA267; Ivabradine for the treatment of chronic heart failure

Final recommendation post consultation

The TA267 guidance should be incorporated into the on-going update of NICE clinical guideline 108 and transferred to the static list.

1. Background

This guidance was issued in November 2012.

At the Guidance Executive meeting of 19 December 2017 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

2. Proposal put to consultees and commentators

The TA267 guidance should be incorporated into the on-going update of NICE clinical guideline 108 and transferred to the static list. That we consult on this proposal.

3. Rationale for selecting this proposal

NICE clinical guideline 108 (Chronic heart failure in adults: management) is currently being updated, with an anticipated publication date of August 2018. Evidence has been identified that suggests ivabradine is clinically effective for people with less-impaired left-ventricular ejection fraction, which may allow the recommendation in TA267 to be broadened. The current TA267 recommendation on ejection fraction includes only people 'with a left ventricular ejection fraction (LVEF) of 35% or less'. However, the number of people affected by this broadening is unknown, so the value of a technology appraisal review may be limited. Therefore, it is proposed that the:

- left ventricular ejection fraction caveat of the recommendation be reviewed in the update of CG108, if considered appropriate by the guideline development team.
- The remaining existing recommendations in TA267 guidance (other than those on LVEF) are transferred to the static list (maintaining the funding direction) because the identified evidence since its initial publication does not suggest that a review of the remaining TA267 recommendations is necessary.

4. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p>Respondent: Servier Laboratories Ltd</p> <p>Response to proposal: Agree</p> <p>I can confirm that Servier is supportive of the proposal to incorporate the TA267 guidance into the on-going update of NICE clinical guideline 108 and transfer the guidance to the static list.</p>	<p>Comment from Technology Appraisals</p> <p>Comments noted. TA267 guidance will be incorporated into the on-going update of NICE clinical guideline 108 and transferred to the static list.</p>
--	---

Paper signed off by: Frances Sutcliffe, 02 March 2018

Contributors to this paper:

Technical Lead: Sharlene Ting

Technical Adviser: Ian Watson

Project Manager: Emily Richards